Ezzat Elhassadi, MD, a consultant hematologist at the University Hospital Waterford in Ireland, discusses the therapeutic approach for different subtypes of mantle cell lymphoma. MCL is a spectrum of diseases that should be treated differently, he says.
Ezzat Elhassadi, MD, a consultant hematologist at the University Hospital Waterford in Ireland, discusses the therapeutic approach for different subtypes of mantle cell lymphoma (MCL). MCL is a spectrum of diseases that should be treated differently, he says.
One subset of patients includes those with indolent disease; physicians should be aware of this subtype as patients with indolent disease typically do not require treatment. However, they can acquire a secondary genetic aberration where they will behave differently and require therapeutic intervention. Elhassadi says, there is also strong evidence that the blastoid variant in MCL will not behave like the classical variant of MCL, and a subset of patients who present with a very high Ki-67 level behave differently than those with low Ki-67, he adds.
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More